CG Oncology CGON Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $1.08M-53.4% | $2.32M+39.4% | $1.67M— | -$0-100% | $52K-88.6% | ||
| $43.73M+46.0% | $29.96M+7.4% | $27.88M-11.0% | $31.33M+14.1% | $27.47M+2.5% | ||
| $20.78M+15.5% | $17.99M-22.9% | $23.33M+34.0% | $17.41M+17.7% | $14.79M+26.3% | ||
| $67.47M+32.2% | $51.02M-3.4% | $52.8M+8.3% | $48.74M+15.3% | $42.26M+9.7% | ||
| -$66.39M-36.3% | -$48.7M+4.8% | -$51.13M-4.9% | -$48.74M-15.5% | -$42.2M-10.9% | ||
| -6,130.1%-4,033pp | -2,097.3%+972pp | -3,069%— | —— | -81,161.5%-72,817pp | ||
| $6.19M-16.3% | $7.39M+1.0% | $7.32M+0.1% | $7.32M-5.6% | $7.75M+24.0% | ||
| -$60.2M-45.7% | -$41.31M+5.7% | -$43.81M-5.8% | -$41.43M-20.2% | -$34.45M-8.3% | ||
| -5,558.8%-3,780pp | -1,779%+851pp | -2,629.5%— | —— | -66,253.8%-59,281pp | ||
| -$0.71-39.2% | -$0.51+10.5% | -$0.57-5.6% | -$0.54-20.0% | -$0.45+6.2% | ||
| -$65.55M-37.0% | -$47.85M+5.6% | -$50.71M-4.4% | -$48.59M-15.2% | -$42.18M-10.9% | ||
| -6,052.4%-3,992pp | -2,060.8%+983pp | -3,044%— | —— | -81,115.4%-72,771pp | ||
| -$66.39M-36.3% | -$48.7M+4.8% | -$51.13M-4.9% | -$48.74M-15.5% | -$42.2M-10.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does CG Oncology's income statement data come from?
- Every line is extracted from CG Oncology's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.